Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

AvePoint’s Robust Performance and Strategic Edge in AI Governance

Robert Sasse by Robert Sasse
December 5, 2025
in AI & Quantum Computing, Analysis, Earnings, Tech & Software
0
AvePoint Stock
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

AvePoint has delivered a standout performance for the third quarter of 2025, surpassing its own targets and accelerating its path to profitability. The data management and AI governance specialist achieved GAAP profitability a full year ahead of its initial schedule. In response to this strong operational momentum, the company has raised its full-year guidance.

Strategic Positioning Meets Market Demand

The company’s impressive results are underpinned by a strategic focus that aligns perfectly with current enterprise challenges. AvePoint’s platforms address critical data security and governance issues, a pressing concern as organizations rapidly adopt artificial intelligence. Notably, the firm cites that 75% of companies using AI experienced security breaches in the past year, while security concerns are slowing further AI adoption at 69% of firms. This positioning allows AvePoint to capitalize directly on a key bottleneck in the AI boom.

Financially, this strategy is translating into powerful growth metrics:
* SaaS revenue surged 38% year-over-year to $84 million.
* Total revenue increased 24% to $109.7 million.
* Annual Recurring Revenue (ARR) grew 26% to $390 million.

A net revenue retention rate of 110% indicates that existing customers are significantly expanding their use of AvePoint’s solutions.

Should investors sell immediately? Or is it worth buying AvePoint?

Revised Guidance and a Strong Balance Sheet

Given this robust performance, management has upgraded its outlook for the full year. The forecast for Annual Recurring Revenue has been lifted to a range of $412.8 million to $418.8 million. Additionally, the expected non-GAAP operating margin has been revised upward to approximately 18.6%–18.8%.

The company is well-financed to support its growth initiatives, boasting a solid balance sheet with $472 million in cash and short-term investments and zero debt. Its dual listing on the Nasdaq and the Singapore Exchange continues to bolster its growth profile, particularly in the Southeast Asian market.

Looking Ahead

For investors, the next key milestone will be the release of fourth-quarter 2025 results, anticipated in late February 2026. Market analysts currently maintain an average rating of “Moderate Buy” on the equity, with a consensus price target of $19.03.

Ad

AvePoint Stock: Buy or Sell?! New AvePoint Analysis from February 8 delivers the answer:

The latest AvePoint figures speak for themselves: Urgent action needed for AvePoint investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

AvePoint: Buy or sell? Read more here...

Tags: AvePoint
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Next Post
ADT Stock

Institutional Investors Drive Significant Accumulation in ADT Shares

ServiceNow Stock

ServiceNow Pursues Dual-Pronged Strategy with Major Acquisition and Stock Split

European Lithium Stock

Setback for European Lithium as Key Austrian Permit Overturned

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com